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Abstract
Purpose of Review The DALI (vitamin D and lifestyle intervention in the prevention of gestational diabetes mellitus (GDM))
study aimed to prevent GDM with lifestyle interventions or Vitamin D supplementation (1600 IU/day). This review summarizes
the learnings from the DALI studies among pregnant women with a BMI ≥ 29 kg/m2.
Recent Findings Women diagnosed with GDM earlier in pregnancy had a worse metabolic profile than those diagnosed later. A
combined physical activity (PA) and healthy eating (HE) lifestyle intervention improved both behaviours, limited gestational
weight gain (GWG) and was cost-effective. Although GDM risk was unchanged, neonatal adiposity was reduced due to less
sedentary time. Neither PA nor HE alone limited GWG or GDM risk. Fasting glucose was higher with HE only intervention, and
lower with Vitamin D supplementation.
Summary Our combined intervention did not prevent GDM, but was cost-effective, limited GWG and reduced neonatal
adiposity.
Keywords Gestational diabetes mellitus . Obesity . Prevention pregnancy . Lifestyle intervention . Vitamin D

Introduction
Gestational diabetes mellitus (GDM) is a common pregnancy
complication and was reported in 2012 to have a European
prevalence of 2–6% [1•]. Obesity is a well-known risk factor
for GDM [2] and the prevalence of both GDM and obesity in
pregnancy is increasing [2–4].Women with GDM have 7.5fold higher risk for the development of type 2 diabetes
mellitus (T2DM), and a nearly 2-fold increased risk of cardiovascular disease (CVD) [5•, 6]. A nearly 3-fold increased
CVD risk was found in those women with a history of
GDM who developed T2DM [7]. Both GDM and obesity
are associated with adverse pre- and perinatal outcomes,
This article is part of the Topical Collection on Diabetes and Pregnancy
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including hypertension, pre-eclampsia, macrosomia, shoulder
dystocia, operative delivery, stillbirth, jaundice and neonatal
hypoglycaemia, as well as higher risk of metabolic disorders
in the offspring [2, 8].
Outside pregnancy, lifestyle interventions have been associated with significant reductions in T2DM development, including among women with past GDM [9••]. Furthermore,
several studies have reported that such lifestyle intervention
strategies in the prevention of T2DM in high-risk populations
are cost-effective [10, 11]. Due to pathophysiological similarities between GDM and T2DM, it is reasonable to postulate
that lifestyle interventions might also be effective during pregnancy to prevent GDM, and that these might be cost-effective.
Similarly, systematic reviews have found an association between risks of hyperglycaemia, including T2DM,
and vitamin D deficiency in non-pregnant adults, with
lower risk of T2DM and lower glucose levels found in
subjects with high 25-hydroxyvitamin D levels [12, 13].
However, results from vitamin D supplementation in patients with T2DM are heterogeneous due to poor quality
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and low participant numbers. Only modest reductions in
HbA1c and no significant differences in fasting glucose
levels have been shown compared with placebo [14].
Recently, the D2d trial including over 2400 patients found
that patients with prediabetes, defined as meeting two of
three criteria for prediabetes (i.e. fasting glucose 100–
125 mg/dl, 2-h postprandial glucose 140–199 mg/dl or
HbA1c 5.7–6.4%) who received vitamin D3 supplementation at a dose of 4000 IU/day had comparable risk for
progression to T2DM (HR 0.88; 95%CI 0.75–1.04;
p = .12) as the placebo group after a 2.5-year follow-up
[15]. Since in pregnancy, associations had been found
between low vitamin D levels and higher risk of GDM
(OR 1.85, 1.47–2.32), higher fasting plasma glucose and
higher HOMA-IR [16], vitamin D supplementation was
thought to be another intervention method to prevent the
progression of GDM in pregnancy at the time the DALI
study was designed.
The DALI (vitamin D and lifestyle intervention in the prevention of GDM) studies were established to describe the
epidemiology of GDM in Europe and to identify intervention
strategies to reduce GDM risk. At the time, the strategies chosen to test to reduce GDM risk were healthy eating (HE) and
physical activity (PA) alone, or together, and vitamin D supplementation at a high enough dose to ensure most obese
women would become replete. The DALI project has generated 15 publications dealing with the epidemiology of GDM
across Europe, effects of lifestyle intervention or vitamin D
supplementation on GDM risk and the offspring, factors mediating intervention effects, cost-effectiveness of GDM prevention methods, mental health in pregnancy and potential
unintended side effects of lifestyle intervention. This paper
summarises the learnings to date, in the context of other publications since DALI commenced in 2012.
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tolerance test (OGTT), pre-existing diabetes, chronic medical
conditions, a psychiatric disorder, walking inability of ≥
100 m, complex diet requirement and language barriers in
the major language of the country of recruitment were exclusion criteria. The International Association of Diabetes and
Pregnancy Study Group (IADPSG)/World Health
Organization (WHO) 2013 criteria were used to diagnose
GDM, which was assessed by OGTT before 20, at 24–28
and 35–37 weeks of gestation (venous plasma glucose: fasting
≥ 5.1 mmol/L, 1 h ≥ 10 mmol/L, 2 h ≥ 8.5 mmol/L).

DALI Lifestyle Intervention
Participating women were either randomised to healthy eating, physical activity, healthy eating and physical activity
(HE&PA) or usual care (UC) in the main trial, whereas in
the pilot study, only the three lifestyle interventions were tested [19••, 20]. The pilot study was performed to test study
processes and to detect limitations and weaknesses, which
needed to be tackled before starting the main trial [21•]. In
the DALI lifestyle trial, seven healthy eating and/or 5 physical
activity messages (Table 1) were conveyed through lifestyle
coaches after randomisation. All interventions were aiming to
achieve a total gestational weight gain of 5 kg in pregnancy,
which is the lower limit of the recommended gestational
weight gain in obese pregnant women according to the
Institute of Medicine [22•].
The lifestyle intervention was based on behavioural and
empowerment techniques using motivational interviewing
methods [23], delivered in 5 face to face meetings with 4
telephone calls/electronic messaging in between. The HE
Table 1

DALI lifestyle intervention messages

Healthy eating messages

DALI Study Design
The DALI studies were conducted between 2012 to 2015 in
11 centres across nine countries in Europe (Austria, Belgium,
Denmark, Ireland, Italy, Poland, Spain, Switzerland, the
Netherlands, United Kingdom). The interventions were tested
in 3 multicentre RCTs, one a pilot and two with a factorial
design [17]. The trial was registered under the number
ISRCTN7059583, was performed according to the declaration
of Helsinki and all local ethics committees approved the study.
Participating women were included before 20 weeks of gestation, with age above 18 years, a pre-pregnancy BMI of ≥
29 kg/m2 and a singleton pregnancy. Data from all DALI sites
were initially analysed to define the BMI cutoff of 29 kg/m2 in
order to allow recruitment of sufficient women as lesser rates
of maternal obesity were found in some participating sites
[18]. A diagnosis of GDM at the baseline oral glucose

1. “Replace sugary drinks”
2. “Eat more non-starchy vegetables”
3. “Increase fibre consumption”
4. “Watch portion size”
5. “Eat more protein”
6. “Reduce fat intake”
7. “Eat less carbohydrates”
Physical activity messages
1. “Be active every day”
2. “Sit less”
3. “Build your strength”
4. “Take more steps”
5. “Be more active at weekends”
(Reproduced from: Jelsma JG, et al. BMC Pregnancy Childbirth.
2013;13:142. doi: https://doi.org/10.1186/1471-2393-13-142; Creative
Commons user licence https://creativecommons.org/licenses/by/4.0/)
[17]
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messages delivered by the coaches were based on food quality
and quantity with focus on intake of complex rather than simple carbohydrates, higher intake of protein and fibre, and reduced fat consumption on the one hand and a focus on portion
size to reduce total daily calorie intake on the other hand. The
PA intervention tried to increase physical activity and reduce
sedentary behaviour by promotion of aerobic and resistance
physical activity. Participating women received a participant
handbook and educational materials, as well as a pedometer
(Digiwalker SW-200; Yamax, Tokyo, Japan), and a flexible
elastic Dyna-Band (Thera-Band, Akron, OH). A mobile technology approach using a handheld electronic device (HTC
HD7, HTC Corporation, Taiwan) was used to support our
coaches [24].

Vitamin D Intervention Trial
In the vitamin D trial of DALI, participating women were
randomised to 4 different groups [25••]. The groups were
either vitamin D or placebo alone or vitamin D or placebo
with lifestyle advice, which was a combination of HE&PA.
Similar cutoff levels of vitamin D in pregnancy to nonpregnant adults were used and thus we aimed to exceed a
vitamin D3 level of ≥ 50 nmol/l at delivery [25••].Vitamin
D3 was supplemented in a dose of 1600 IU daily starting in
early pregnancy before 20 weeks of gestation [25••]. The dose
of 1600 IU/day was chosen to account for a total intake of
2000 IU/day with supplements considering a high proportion
of women taking multivitamins in pregnancy with an average
vitamin D3 content of 400 IU per tablet. Initially, in the pilot
study, a vitamin D dosing and safety trial was planned, which
was not executed due to external research results published
shortly before pilot start and demonstrating a safe and sufficient application of vitamin D in pregnancy in higher doses
than planned in DALI [26•]. Furthermore, the upper tolerable
intake in pregnancy was increased to 4000 IU/day at the same
time [27]. Vitamin D3 (Devaron®) with a dose of 400 IU per
tablet and identical placebo tablets were produced by Vemedia
(Diemen, Netherlands). In the vitamin D trial, the beneficial
effects of supplementation of vitamin D3 with or without lifestyle intervention on prevention of GDM assessed by fasting
glucose, HOMA IR and weight gain compared with placebo
with and without lifestyle intervention were tested as well as
safe application.

Process Evaluation and Fidelity
In a process evaluation of the interventions in the DALI pilot
study, relevant knowledge about the implementation process
of lifestyle intervention delivered with behavioural techniques
based on motivational interviewing in obese pregnant women
was gathered [20]. DALI was a Pan-European trial and thus
different languages and cultures made it challenging to deliver
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the same intervention messages to the participating women
across all sites and so a process evaluation was important to
find restrictions and limitations as well as positive aspects of
the intervention. When using motivational interviewing techniques, a quality assessment of the intervention is recommended to identify the effect of the interventions on the outcome [28]. A majority of women (63%) received all intervention sessions and reported high satisfaction with several intervention aspects (ratings 7.6–9.2 out of 10 points for maximum
satisfaction). However, across sites high variability of motivational interviewing competency of lifestyle coaches was reported. Several global motivational interviewing scores were
assessed to evaluate fidelity and beginning proficiency or almost beginning proficiency was reached by the coaches,
mostly. However, the overall motivational interviewing scores
were below expert cutoffs. Associations between the process
elements fidelity and dose, which are a level of coaching proficiency or number of contacts, and gestational weight gain
were not detected. A need for further studies in this field to
find solutions to attract non-responders as well as increased
feedback possibilities and recording facilities throughout the
study was reported to be potentially helpful to increase motivational interviewing fidelity [20].
Preferences and perceived barriers of the DALI participants
were analysed. Obese women indicated that offspring health
was a main driver to participate in an intervention study, but
barriers such as tiredness, pain or physical limitations and lack
of time due to child care were named as one of the main
barriers for physical activity [29]. Proper background knowledge about risk in pregnancy was rated important, as well as
flexibility and individual modification of the intervention and
partner support.

Epidemiology of GDM
In DALI, a total GDM prevalence of 39% was detected across
early, mid and late gestation [30••]. Former prevalence data
found tremendously lower GDM rates of 2–6% in a retrospective analysis and including women of all BMI categories [1•].
These differences might be explained through different
screening modalities (universal vs. risk-based) and different
diagnostic criteria as well as poor clinical awareness [1•]. In
DALI, with identical protocols for screening and diagnosis in
all countries, higher rates were detected in Northern Europe
with a prevalence of 52% in Denmark, whereas lower rates
were found in Western Europe with a prevalence of 24% and
25% in the UK and Ireland [30••]. These large variations between countries were unexpected. A high rate of GDM was
found in early pregnancy with 24% (prevalent GDM, i.e.
women presenting with GDM already at first examination),
with a further 14% and then 13% new cases (incident GDM,
i.e. developing GDM de novo during pregnancy) at 24–28 and
35–37 weeks respectively. As many European countries were
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involved, and different clinical routines were in place, there is
a risk that the differences in GDM prevalence might be explained by different sample processing. To diminish the
chance of such variation in sample handling and collection,
strict standard operating procedures were defined before trial
start, and tested in a pilot study to assure identical processing
across all countries. All samples were stored immediately at −
20 °C or below and centrally analysed in the ISO-certified
laboratory of the Medical University of Graz. Nonmodifiable risk factors for the development of GDM (women
developing GDM vs. those maintaining a normal OGTT respectively) [30••, 31] included recruitment site, lower maternal height, previous GDM (16.5% vs. 7.9%, p < 0.01), past
babies with congenital malformations (6.4% vs. 3.3%,
p < 0.05) and previous macrosomia (31.4% vs. 17.9%,
p < 0.01). Potentially modifiable risk factors included larger
neck circumference and higher resting heart rate [31].
Pregnancy outcomes did not differ overall between women
with normal glucose tolerance and women with GDM developing mid-late pregnancy.

Heterogeneity of GDM
Compared with women with a later diagnosis of GDM, women diagnosed with GDM before 20 weeks of gestation had
higher insulin resistance, BMI, waist circumference, blood
pressure and heart rate as well as lipids, which are all features
of the metabolic syndrome [32•]. Nearly 80% of these women
were identified by increased fasting glucose. The presence of
early GDM (compared with early normal glucose tolerance)
was associated with higher pre-pregnancy BMI (OR 1.05,
95% CI 1.00–1.10, per kg/m2) and sum of skinfolds (1.01,
95% CI 1.00–1.02, per mm), a history of GDM (2.74, 95%
CI 1.66–4.50) and macrosomia (1.97, 95% CI 1.03–3.98)
[32•]. This led us to wonder whether women diagnosed early
had likely mild hyperglycaemia before conception and therefore could be considered to have prevalent GDM, while women developing GDM de novo after this time had incident
GDM. Further work is urgently needed into the genotype,
phenotype and natural history of what seem to be two types
of GDM.

The Effect of Lifestyle Intervention on GDM Risk,
Potential Limitations of Lifestyle Intervention
and Neonatal Outcomes
In the main lifestyle trial, the combined HE&PA group had
significantly lower gestational weight gain (− 2.02, 95% CI −
3.58 to − 0.46 kg) compared with UC, which did not affect
fasting glucose, HOMA-IR or birth outcomes [19••].
Gestational weight gain was not significantly different to UC
in groups with HE or PA alone [19••]. The lifestyle intervention had significant effects on nutrition and PA in the
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participants. Greater moderate to vigorous physical activity
(MVPA) was found in the PA group (0.36, 95% CI 0.13 to
0.60 METh/wk) at 24–28 weeks of pregnancy and in HE&PA
sedentary behaviour was decreased at 24 to 28 (− 3.0, 95% CI
− 4.47 to − 0.45 METh/wk) and 35 to 37 weeks (− 2.98, 95%
CI − 5.29 to − 0.67 METh/wk) compared with UC. Nutrition
improved in HE with a reduced intake of sugared drinks,
carbohydrates and portion size and higher vegetable intake.
Reduced portion size and higher vegetable intake were found
in the combined HE&PA group in comparison with UC
[19••].
In a post hoc analysis, even a gestational weight gain limitation of 2.6 kg at 24–28 and 4.3 kg at 35–37 weeks of
gestation (i.e. 6.7 ± 5.9 vs. 4.1 ± 5.0 and 11.3 ± 6.7 vs. 7.0 ±
6.0 kg, p < 0.05 both) had no impact on metabolic outcomes
but reduced the frequency of large for gestational age babies
(25% vs 16% p < 0.05). [33•]. Increased fasting glucose was
found in the HE group, and because less carbohydrate intake
was reported in this group, higher lipolysis was speculated as a
potential explanation for increased fasting glucose. Increased
free fatty acid levels were also reported in the cord blood from
the offspring of the HE group (0.34 ± 0.22 vs. 0.29 ±
0.16 mmol/L p = 0.01) [34••]. No maternal or fetal differences
were found between the PA vs. no PA intervention groups
[34••].
In the combined HE&PA group, an analysis of the effects
of lifestyle intervention on offspring outcomes found lower
adiposity (sum of skinfolds, fat mass and percentage and cord
blood leptin levels) compared with UC [35••]. Lower cord
blood leptin levels were also reported in female offspring in
the PA group. A mediation analysis showed that the decrease
in sedentary time in HE&PA and PA groups mediated the
intervention effects on neonatal adiposity. Interestingly, the
reduction in GWG did not mediate these effects.

Psychological Aspects
In a further analysis, mediators of behaviour change
were analysed and an increased task self-efficacy (defined as one’s belief in one’s ability to succeed in specific situations or accomplish a task) was identified to
be the main element to improve health behaviour [36].
The improvements in this factor had mediatory effects
on physical activity and decreased intake of sugared
drinks and portion size.
In a study testing the association of mental health status and
MVPA or sedentary behaviour measured with accelerometers,
27.1% of the pregnant women had depressed mood with a
WHO-5 well-being index score < 50 before 20 weeks of gestation [37•]. Pregnancy-related worries and lower perceived
social support were significantly higher in these women.
Women with good mental health status at baseline spent
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significantly more time in MVPA compared with women with
depressed mood (24 min vs. 13 min/day), whereas pregnancyrelated worries did not affect MVPA time. In an adjusted linear regression model, women with good mental health at baseline spent 85% more time doing MVPA compared with those
with depressed mood (p < 0.05) [37•]. MVPA of at least
30 min was achieved by only 29.6% of women.
Before 20 weeks of gestation, several maternal characteristics were found to be associated with low mental health
status [38]. European ethnicity, social support as well as selfefficacy were protective factors, whereas shift work, lack of
sleep and pregnancy-related worries increased risk for low
well-being in early pregnancy [38].

Vitamin D and GDM Risk
In the DALI Vitamin D trial, 25-hydroxyvitamin D baseline
levels exceeding 50 nmol/l were reported across all study centres [25••], which was an unexpected finding as previous studies had suggested that a majority of obese pregnant women
would have low vitamin D levels [39, 40]. Supplementation of
25-hydroxyvitamin D resulted in greater sufficiency in the
vitamin D arm, with significant differences in levels compared
with placebo at 24–28 (97 vs. 74%) and 35–37 (98 vs. 78%,
p < 0.001 both) weeks gestation. Interestingly, lower fasting
glucose was found in the vitamin D group compared with
placebo (− 0.14, 95% CI − 0.28–0.00 mmol/l) at 35–
37 weeks gestation; however, this difference was thought to
be too small and too late to be clinically significant. No other
metabolic or perinatal effects were found.

Cost-effectiveness
DALI evaluated cost-effectiveness of lifestyle intervention
compared with UC in pregnancies at high risk for GDM and
found that the HE&PA intervention was the preferred prevention strategy for limitation of gestational weight gain at 35–
37 weeks, and was cost-effective for quality-adjusted life
years (QALYs) after delivery [41•], with an average saving
of €91,254 per QALY gained. No cost-effectiveness was
found for any of the lifestyle interventions for fasting glucose
or HOMA-IR at 35–37 weeks.

Discussion
The DALI lifestyle trial was one of 4 large RCTs to test whether GDM could be prevented by lifestyle interventions [17, 18,
20, 24]. The DALI vitamin D trial was one of only several
trials to try to prevent GDM using vitamin D [25••]. The
epidemiological, behavioural and pathophysiological
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evidence that the DALI studies have generated have added
significantly to our understanding of GDM.
DALI demonstrated that in a multicentre, multicultural
setting, the implementation of behavioural lifestyle intervention is challenging but possible. Coaches with good
training can achieve beginning professional level quickly
and are able to deliver motivational interviewing-based
lifestyle intervention in a high quality with high fidelity.
Nonetheless, there is a need for more information about
the implementation of such strategies in diabetes prevention studies and the success of such interventions using
coaches with limited experience of motivational
interviewing.

Women with Prevalent GDM
A key strength of DALI is that it used uniform IADPSG/
WHO criteria in all centres across Europe from early pregnancy to 35–37 weeks. The trials were conducted having excluded those women with early (prevalent) GDM (i.e. a diagnostic
OGTT on screening for the study). Subsequent to the commencement of the studies, the IADPSG determined that it was
unclear which criteria should be used early in pregnancy. It
may be that diagnostic thresholds should be higher (DALI
excluded some women without GDM but at the higher end
of the ‘normal’ glycaemic spectrum). DALI therefore was
potentially limited by excluding women who might be considered not to have GDM once criteria at this early stage are
developed. If so, such women would be at the top end of the
glucose range, and may have benefited from lifestyle change.
Using these IADPSG criteria, DALI was able to demonstrate a
high prevalence of GDM in women with BMI above 29 kg/m2
and high variation of GDM across Europe. Risk factors identified at several time points in pregnancy were mostly nonmodifiable. The studies have also shown the different proportions of women with prevalent GDM and the additional 40–
60% developing GDM after excluding those with early GDM.
Women with early/prevalent GDM clearly feature characteristics of the metabolic syndrome compared with women with
GDM in later pregnancy. These data highlight the need for
uniform diagnostic criteria and, if early treatment is shown
to be beneficial, systematic screening starting in early pregnancy in high-risk groups [1•]. Nonetheless, the IADPSG/
WHO criteria were not validated for use in early pregnancy
before 20 weeks of gestation and studies are ongoing to do so
[42, 43]. Results from the treatment of booking gestational
diabetes mellitus (TOBOGM) pilot study indicate that the
decision over which criteria to use may be complex, with early
treatment resulting in less large for gestational age babies, but
perhaps more babies requiring neonatal intensive care unit
admission [44••].
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Comparison with Other Lifestyle Intervention
Trials
The DALI lifestyle intervention studies demonstrated that
early behavioural intervention approaches were successful
in reducing maternal weight gain significantly compared
with prior intervention studies but did not have effects
on glucose metabolism. Several large scale antenatal lifestyle intervention trials have been conducted aiming to
prevent gestational diabetes mellitus (GDM) yielding conflicting results [45••, 46••, 47••]. Such trials have included
high-risk populations including overweight or obese women or women with a history of GDM. The LIMIT and
UPBEAT trials were the largest lifestyle intervention trials
and included overweight or obese mothers [45••, 46••].
They used a combination of nutritional and physical activity interventions but were not able to reduce the risk of
GDM development compared with the control group with
standard antenatal care. Noticeable was the relatively low
and non-significant difference in gestational weight gain
between intervention and control group in LIMIT (0 kg)
and UPBEAT (−0.5 kg), which might have not been
enough to overcome insulin resistance in the intervention
groups [48, 49]. RADIEL was designed slightly differently
with regard to the study population (overweight, many
with a history of GDM) but also used healthy eating
and physical activity intervention methods and reported a
significant GDM reduction of 39% in the intervention
group compared with the control group after correction
for baseline parameters [47••].
According to a Cochrane review, nutritional and exercise
approaches have the potential to prevent GDM (RR 0.85, 95%
CI 0.71 to 1.01); however, a huge heterogeneity between studies, improper definition of interventions and description of
behavioural change dynamics were reported, and there was
no significant effect on GDM development [50]. An older
systematic review of 29 lifestyle RCTs found a GDM risk
reduction of 18% (RR 0.82 95% CI 0.70–0.95) with nutritional and exercise interventions overall. This reduction was primarily based on a significant risk reduction of GDM in studies
with lifestyle interventions beginning before 15 weeks gestation (RR 0.78, 95% CI 0.64 to 0.96), whereas no significant
GDM risk reduction was seen thereafter (RR 0.97, 95% CI
0.82 to 1.13) [51]. The DALI (vitamin D and lifestyle intervention in the prevention of GDM) trial was the first
multicentre, randomised controlled study across 9 countries
in Europe [17, 19••, 25••].

Factors Affecting Lifestyle Intervention
Egan and Simmons [8] discussed several aspects which might
be relevant in the explanation of differences in outcomes of
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lifestyle trials. The heterogeneity of GDM itself with a variety
of insulin secretory or insulin resistance or even mixed defects
might be a cause of these differences, which needs further
investigation [52]. Lifestyle changes are difficult to achieve
and especially with increasing gestational week maintaining
lifestyle goals might be hard. In a recent US study, below 10%
of pregnant women managed to achieve the recommended PA
of 5 days per week in the third trimester [53]. Weight gain is a
relevant factor in GDM development. However, contrary to
outside pregnancy, unlimited weight loss is not an option in
pregnancy as this is related to fetal undernutrition and the
potential programming of cardiometabolic disease and development of those in later adult life. Further research is needed
in this field.
Psychosocial aspects are relevant factors in pregnancy and
may have effects on lifestyle and thus lifestyle intervention. In
general, a greater need for physical activity intervention is
necessary in obese women with depression. Obesity, a depressed mood and an unhealthy lifestyle are potential additional risk factors for maternal and fetal pregnancy complications [37•, 54]. However, it is unclear if and to what extent
lifestyle intervention can sufficiently improve MVPA in a
group of depressed women as low mental health status may
impede these ambitions. Thus, further research is needed to
Table 2

Summarized important lessons learned from the DALI trials

• High prevalence of GDM in early and throughout pregnancy in obese
pregnant women using IADPSG/WHO 2013 criteria.
• GDM before 20 weeks of gestation was associated with features of the
metabolic syndrome and insulin resistance compared with women with
normal glucose tolerance.
• Risk factors for GDM vary between trimesters and were mostly of
non-modifiable nature.
• Lifestyle intervention starting after the first trimester did not improve
glucose levels or insulin resistance although significantly less weight
gain was seen in the combined healthy eating and physical activity
(HE&PA) lifestyle intervention.
• Healthy behaviour increased in the lifestyle intervention groups.
• Mental well-being in pregnant women was associated with increased
physical activity.
• Gestational weight gain reduction was not associated with improved
glycaemic control but was associated with lower rates of babies born
large for gestational age.
• The combined intervention of healthy eating and physical activity
(HE&PA) reduced fetal adiposity. This was mediated by a reduction in
sedentary behaviour.
• Other mediating factors for improved maternal health behaviour were
identified.
• The healthy eating intervention was associated with increased maternal
and fetal free fatty acid levels possibly due to increased lipolysis and
increased maternal fasting glucose.
• Cost-effectiveness was shown for HE&PA—the intervention was
cost-effective for quality-adjusted life years after delivery.
• Vitamin D supplementation had low, clinically insignificant effects on
glucose levels and no effect on birth outcomes.
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investigate the effects of lifestyle intervention with regard to
mental health status.
Taken together, DALI found that a lifestyle intervention
was not able to prevent GDM from the second trimester but
was cost-effective, limited gestational weight gain and improved pregnancy outcomes. A summary of important lessons
learned from DALI is shown in Table 2. Several other interesting and useful findings will help to improve future intervention trials and the health outcome of mothers and their
offspring.

Roland Devlieger, PhD 5KU Leuven Department of
Development and Regeneration: Pregnancy, Fetus and
Neonate. Gynaecology and Obstetrics, University Hospitals
Leuven, Belgium. E: roland.devlieger@uzleuven.be

Compliance with Ethical Standards

Elizabeth Reinhardt Mathiesen, DMsc. 6 Center for
Pregnant Women with Diabetes, Departments of
Endocrinology and Obstetrics, Rigshospitalet, Institute of
Clinical Medicine, Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark. E:
elisabeth.reinhardt.mathiesen@regionh.dk

The trial was registered
under the number ISRCTN7059583, was performed according to the
declaration of Helsinki and all local ethics committees approved the
study.
Conflict of Interest Jürgen Harreiter, Gernot Desoye, Mireille van
Poppel, Alexandra Kautzky-Willer, Fidelma Dunne, Rosa Corcoy,
Roland Devlieger and David Simmons declare that they have no conflict
of interest.
Human and Animal Rights and Informed Consent The studies included
humans all of whom gave informed consent.

Appendix The DALI core investigators group
G. Desoye1, D. Simmons2, R. Corcoy3,4, J.M. Adelantado3, R.
Devlieger5, P. Damm6, E.R. Mathiesen6, D.M. Jensen7, L.L.
Andersen7, A. Lapolla8, MG. Dalfrà8, A Bertolotto9, E.
Wender-Ozegowska10, A. Zawiejska10, D J. Hill11, M.N.M.
van Poppel12, F.J. Snoek13, A. Kautzky-Willer14, FP. Dunne15
Gernot Desoye, PhD 1 Department of Obstetrics and
Gynaecology, Medizinische Universitaet Graz, Graz,
Austria. E: gernot.desoye@medunigraz.at
David Simmons, MD (Cantab) 2Institute of Metabolic
Science, Addenbrookes Hospital, Cambridge, England and
Macarthur Clinical School, Western Sydney University,
Sydney, Australia. E: Da.simmons@westernsydney.edu.au
Rosa Corcoy, PhD 3Institut de Recerca de l’Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain; Departament de
Medicina, Universitat Autònoma de Barcelona, Bellaterra,
Spain.
4

CIBER Bioengineering, Biomaterials and Nanotechnology,
Instituto de Salud Carlos III, Zaragoza, Spain E:
RCorcoy@santpau.cat
Juan M Adelantado, PhD 3Institut de Recerca de l’Hospital
de la Santa Creu i Sant Pau, Barcelona, Spain. E:
JAdelantado@santpau.cat

Peter Damm, DMsc. 6Center for Pregnant Women with
Diabetes, Departments of Endocrinology and Obstetrics,
Rigshospitalet, Institute of Clinical Medicine, Faculty of
Health and Medical Sciences, University of Copenhagen,
Copenhagen, Denmark. E: pdamm@dadlnet.dk

Dorte Moeller Jensen, PhD 7Department of Endocrinology
and Department of Gynaecology and Obstetrics, Odense
University Hospital, Department of Clinical Research,
Faculty of Health Science, University of Southern Denmark,
Odense, Denmark. E: Dorte.Moeller.Jensen@rsyd.dk
Lise Lotte T. Anderson, MD. 7Department of Endocrinology
and Department of Gynaecology and Obstetrics, Odense
University Hospital, Department of Clinical Research, Faculty
of Health Science, University of Southern Denmark, Odense,
Denmark. E: lise.lotte.andersen@rsyd.dk
Annunziata Lapolla, MD 8Universita Degli Studi di
Padova, Padua, Italy. E: annunziata.lapolla@unipd.it
Maria G Dalfrà, MD 8Universita Degli Studi di Padova,
Padua, Italy. E: u053734@sanita.padova.it
Alessandra Bertolotto, PhD. 9 Azienda OspedalieroUniversitaria Pisana, Pisa, Italy. E: alessandrabertolotto1959
@yahoo.it
E w a We n d e r- O z e g o w s k a , P h D . 1 0 D i v i s i o n o f
Reproduction, Poznan University of Medical Sciences,
Poznan, Poland. E: ewaoz@post.pl
Agnieszka Zawiejska, PhD 10Division of Reproduction,
Poznan University of Medical Sciences, Poznan, Poland E:
agazaw@post.home.pl
David J.Hill, DPhil. 11Recherche en Santé Lawson SA, St.
Gallen, Switzerland. E: david.hill@lawsonresearch.com
Mireille N.M. van Poppel, PhD. 12Department of Public
and Occupational Health, EMGO+-Institute for Health and
Care Research, VU University Medical Centre, Amsterdam,

162

Page 8 of 10

the Netherlands and Institute of Sport Science, University of
Graz, Graz, Austria. E: mireille.van-poppel@uni-graz.at
Frank J Snoek, PhD 13Department of Medical Psychology,
EMGO+-Institute for Health and Care Research, VU
University Medical Centre and Medical Psychology AMC,
Amsterdam, the Netherlands. E: fj.snoek@vumc.nl
Alexandra Kautzky-Willer, MD 14Gender Medicine Unit,
Division of Endocrinology and Metabolism, Department of
Medicine III, Medical University of Vienna, Vienna, Austria.
E: alexandra.kautzky-willer@meduniwien.ac.at
Fidelma Dunne, PhD 15National University of Ireland,
Galway, Ireland. E: fidelma.dunne@nuigalway.ie

References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1.• Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D,
et al. Gestational diabetes mellitus in Europe: prevalence, current
screening practice and barriers to screening. A review. Diabet Med.
2012;29(7):844–54. Review showing inconsistencies regarding
GDM diagnostic criteria as well as other aspects hampering
GDM screening and treatment across Europe.
2. Simmons D. Diabetes and obesity in pregnancy. Best Pract Res Clin
Obstet Gynaecol. 2011;25(1):25–36.
3. Ferrara A. Increasing prevalence of gestational diabetes mellitus: a
public health perspective. Diabetes Care. 2007;30(Suppl 2):S141–
6.
4. Lavery JA, Friedman AM, Keyes KM, Wright JD, Ananth CV.
Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. BJOG. 2017;124(5):804–13.
5.• Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes
mellitus after gestational diabetes: a systematic review and metaanalysis. Lancet. 2009;373(9677):1773–9. Systematic review describing the high risk of T2DM in women with a history of
GDM.
6. Harreiter J, Dovjak G, Kautzky-Willer A. Gestational diabetes
mellitus and cardiovascular risk after pregnancy. Women’s Health
(Lond Engl). 2014;10(1):91–108.
7. Retnakaran R, Shah BR. Role of type 2 diabetes in determining
retinal, renal, and cardiovascular outcomes in women with previous
gestational diabetes mellitus. Diabetes Care. 2017;40(1):101–8.
8. Egan AM, Simmons D. Lessons learned from lifestyle prevention
trials in gestational diabetes mellitus. Diabet Med. 2019;36(2):142–
50.
9.•• Aroda VR, Christophi CA, Edelstein SL, Zhang P, Herman WH,
Barrett-Connor E, et al. The effect of lifestyle intervention and
metformin on preventing or delaying diabetes among women with
and without gestational diabetes: the diabetes prevention program
outcomes study 10-year follow-up. J Clin Endocrinol Metab.
2015;100(4):1646–53. Follow-up subanalysis of the DPP focussing on women with a history of GDM and describing the

Curr Diab Rep

(2019) 19:162

effects of lifestyle intervention, metformin versus placebo on
diabetes risk after 10 years.
10. Alouki K, Delisle H, Bermudez-Tamayo C, Johri M. Lifestyle interventions to prevent type 2 diabetes: a systematic review of economic evaluation studies. J Diabetes Res. 2016;2016:2159890.
11. Li R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Costeffectiveness of interventions to prevent and control diabetes
mellitus: a systematic review. Diabetes Care. 2010;33(8):1872–94.
12. Ekmekcioglu C, Haluza D, Kundi M. 25-Hydroxyvitamin D status
and risk for colorectal cancer and Type 2 diabetes mellitus: a systematic review and meta-analysis of epidemiological studies. Int J
Environ Res Public Health. 2017;14(2):127. https://doi.org/10.
3390/ijerph14020127.
13. Rafiq S, Jeppesen PB. Is Hypovitaminosis D Related to incidence
of Type 2 diabetes and high fasting glucose level in healthy subjects: a systematic review and meta-analysis of observational studies. Nutrients. 2018;10(1):59. https://doi.org/10.3390/nu10010059.
14. Lee CJ, Iyer G, Liu Y, Kalyani RR, Bamba N, Ligon CB, et al. The
effect of vitamin D supplementation on glucose metabolism in type
2 diabetes mellitus: a systematic review and meta-analysis of intervention studies. J Diabetes Complicat. 2017;31(7):1115–26.
15. Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC,
Aroda VR, et al. Vitamin D supplementation and prevention of type
2 diabetes. N Engl J Med. 2019;381(6):520–30.
16. Zhang Y, Gong Y, Xue H, Xiong J, Cheng G. Vitamin D and
gestational diabetes mellitus: a systematic review based on data free
of Hawthorne effect. BJOG. 2018;125(7):784–93.
17. Jelsma JG, van Poppel MN, Galjaard S, Desoye G, Corcoy R,
Devlieger R, et al. DALI: vitamin D and lifestyle intervention for
gestational diabetes mellitus (GDM) prevention: an European
multicentre, randomised trial - study protocol. BMC Pregnancy
Childbirth. 2013;13:142. https://doi.org/10.1186/1471-2393-13-142.
18. Vellinga A, Zawiejska A, Harreiter J, Buckley B, Di Cianni G,
Lapolla A, et al. Associations of body mass index (maternal BMI)
and gestational diabetes mellitus with neonatal and maternal pregnancy outcomes in a multicentre European database (diabetes and
pregnancy vitamin D and lifestyle intervention for gestational diabetes mellitus prevention). ISRN Obes. 2012;2012:424010.
19.•• Simmons D, Devlieger R, van Assche A, Jans G, Galjaard S,
Corcoy R, et al. Effect of physical activity and/or healthy eating
on GDM risk: the DALI lifestyle study. J Clin Endocrinol Metab.
2017;102(3):903–13. DALI main lifestyle intervention study describing effects of healthy eating, physical activity or a combined group versus usual care on gluco-metabolic outcomes in
pregnancy.
20. Jelsma JGM, Simmons D, Gobat N, Rollnick S, Blumska K, Jans
G, et al. Is a motivational interviewing based lifestyle intervention
for obese pregnant women across Europe implemented as planned?
Process evaluation of the DALI study. BMC Pregnancy Childbirth.
2017;17(1):293.
21.• Simmons D, Jelsma JG, Galjaard S, Devlieger R, van Assche A,
Jans G, et al. Results from a European multicenter randomized trial
of physical activity and/or healthy eating to reduce the risk of gestational diabetes mellitus: the DALI lifestyle pilot. Diabetes Care.
2015;38(9):1650–6. Pilot study of the DALI trial testing the lifestyle interventions and study procedures.
22.• IOM (Institute of Medicine) and NRC (National Research Council).
Weight gain during pregnancy: reexamining the guidelines.
Washington, DC: The National Academies Press. 2009. Criteria
for recommended weight gain in pregnancy according to prepregnancy BMI.
23. Miller WR, Rollnick S. Motivational interviewing, preparing people to change addictive behavior. New York: The Guildford Press;
1991.

Curr Diab Rep
24.

25.••

26.•

27.

28.

29.

30.••

31.

32.•

33.•

34.••

35.••

(2019) 19:162

Simmons D, Daniels T, Simmons DJ, van Poppel M, Harreiter J. A
Mobile electronic record for lifestyle coaches in gestational diabetes
prevention. JMTM. 2019;8(1):37–49.
Corcoy R, Mendoza LC, Simmons D, Desoye G, Adelantado JM,
Chico A, et al. The DALI vitamin D randomized controlled trial for
gestational diabetes mellitus prevention: no major benefit shown
besides vitamin D sufficiency. Clin Nutr. 2019; (in press). https://
doi.org/10.1016/j.clnu.2019.04.006. DALI vitamin D trial
describing the effects of Vitamin D3 supplementation on
gluco-metabolic outcomes in pregnancy.
Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL.
Vitamin D Supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner
Res. 2011;26(10):2341–57. Vitamin D dosage and safety trial
in pregnancy.
Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton
SK, et al. The 2011 report on dietary reference intakes for calcium
and vitamin D from the Institute of Medicine: what clinicians need
to know. J Clin Endocrinol Metab. 2011;96(1):53–8.
Miller WR, Rollnick S. The effectiveness and ineffectiveness of
complex behavioral interventions: impact of treatment fidelity.
Contemp Clin Trials. 2014;37(2):234–41.
Jelsma JG, van Leeuwen KM, Oostdam N, Bunn C, Simmons D,
Desoye G, et al. Beliefs, barriers, and preferences of European
overweight women to adopt a healthier lifestyle in pregnancy to
minimize risk of developing gestational diabetes mellitus: an explorative study. J Pregnancy. 2016;2016:3435791.
Egan AM, Vellinga A, Harreiter J, Simmons D, Desoye G, Corcoy
R, et al. Epidemiology of gestational diabetes mellitus according to
IADPSG/WHO 2013 criteria among obese pregnant women in
Europe. Diabetologia. 2017;60(10):1913–21. DALI epidemiology
paper describing GDM prevalence throughout Europe and risk
factors.
Mendoza LC, Harreiter J, Simmons D, Desoye G, Adelantado JM,
Juarez F, et al. Risk factors for hyperglycemia in pregnancy in the
DALI study differ by period of pregnancy and OGTT time point.
Eur J Endocrinol. 2018;179(1):39–49.
Harreiter J, Simmons D, Desoye G, Corcoy R, Adelantado JM,
Devlieger R, et al. IADPSG and WHO 2013 gestational diabetes
mellitus criteria identify obese women with marked insulin resistance in early pregnancy. Diabetes Care. 2016;39(7):e90–2.
Features of the MetSy in obese pregnant women with GDM
diagnosis before 20 weeks of gestation.
Simmons D, Devlieger R, van Assche A, Galjaard S, Corcoy R,
Adelantado JM, et al. Association between gestational weight gain,
gestational diabetes risk, and obstetric outcomes: a randomized
controlled trial post hoc analysis. Nutrients. 2018;10(11):1568.
Secondary analysis describing the effects of weight gain on
gluco-metabolic as well as birth outcomes.
Harreiter J, Simmons D, Desoye G, Corcoy R, Adelantado JM,
Devlieger R, et al. Nutritional lifestyle intervention in obese pregnant women, including lower carbohydrate intake, is associated
with increased maternal free fatty acids, 3-beta-hydroxybutyrate,
and fasting glucose concentrations: a secondary factorial analysis
of the European multicenter, randomized controlled DALI lifestyle
intervention trial. Diabetes Care. 2019;42(8):1380–9. Secondary
analysis describing the effects of lifestyle intervention on maternal and fetal lipid metabolism, increased lipolysis was observed,
which was associated with increased fasting glucose.
van Poppel MNM, Simmons D, Devlieger R, van Assche FA, Jans
G, Galjaard S, et al. A reduction in sedentary behaviour in obese
women during pregnancy reduces neonatal adiposity: the DALI
randomised controlled trial. Diabetologia. 2019;62(6):915–25.
Beneficial effects of combined healthy eating and physical activity on neonatal adiposity intervention was observed.

Page 9 of 10 162
36.

37.•

38.

39.

40.
41.•

42.

43.

44.••

45.••

46.••

47.••

48.

49.

50.

van Poppel MN, Jelsma JGM, Simmons D, Devlieger R, Jans G,
Galjaard S, et al. Mediators of lifestyle behaviour changes in obese
pregnant women. Secondary analyses from the DALI lifestyle
randomised controlled trial. Nutrients. 2019;11(2):311. https://doi.
org/10.3390/nu11020311.
de Wit L, Jelsma JG, van Poppel MN, Bogaerts A, Simmons D,
Desoye G, et al. Physical activity, depressed mood and pregnancy
worries in European obese pregnant women: results from the DALI
study. BMC Pregnancy Childbirth. 2015;15:158. Secondary analysis describing the associations of maternal well being and
physical activity in pregnancy.
Sattler MC, Jelsma JGM, Bogaerts A, Simmons D, Desoye G,
Corcoy R, et al. Correlates of poor mental health in early pregnancy
in obese European women. BMC Pregnancy Childbirth.
2017;17(1):404.
Bodnar LM, Catov JM, Roberts JM, Simhan HN. Prepregnancy
obesity predicts poor vitamin D status in mothers and their neonates. J Nutr. 2007;137(11):2437–42.
McAree T. Obesity and vitamin D deficiency - current concepts on
their impact on pregnancy. Eur Endocrinol. 2013;9(2):125–7.
Broekhuizen K, Simmons D, Devlieger R, van Assche A, Jans G,
Galjaard S, et al. Cost-effectiveness of healthy eating and/or physical activity promotion in pregnant women at increased risk of
gestational diabetes mellitus: economic evaluation alongside the
DALI study, a European multicenter randomized controlled trial.
Int J Behav Nutr Phys Act. 2018;15(1):23. Cost-effectiveness
analysis of the DALI interventions.
Simmons D, Hague WM, Teede HJ, Cheung NW, Hibbert EJ,
Nolan CJ, et al. Hyperglycaemia in early pregnancy: the treatment
of booking gestational diabetes mellitus (TOBOGM) study. A
randomised controlled trial. Med J Aust. 2018;209(9):405–6.43.
McIntyre HD, sacks DA, Barbour LA, Feig DS, Catalano PM,
Damm P, et al. Issues with the diagnosis and classification of hyperglycemia in early pregnancy. Diabetes Care. 2016;39(1):53–4.
Simmons D, Nema J, Parton C, Vizza L, Robertson A, Rajagopal R,
et al. The treatment of booking gestational diabetes mellitus
(TOBOGM) pilot randomised controlled trial. BMC Pregnancy
Childbirth. 2018;18(1):151. Pilot study of an ongoing trial testing
effects of early GDM treatment versus late GDM treatment and
the effects on pregnancy and birth outcomes.
Poston L, Bell R, Croker H, Flynn AC, Godfrey KM, Goff L, et al.
Effect of a behavioural intervention in obese pregnant women (the
UPBEAT study): a multicentre, randomised controlled trial. Lancet
Diabetes Endocrinol. 2015;3(10):767–77. Effects of lifestyle intervention in obese women on LGA infants and glucose metabolism in pregnancy.
Dodd JM, Turnbull D, McPhee AJ, Deussen AR, Grivell RM,
Yelland LN, et al. Antenatal lifestyle advice for women who are
overweight or obese: LIMIT randomised trial. BMJ. 2014;348:
g1285. Effects of lifestyle intervention in overweight/obese
women on LGA infants and glucose metabolism in pregnancy.
Koivusalo SB, Rono K, Klemetti MM, Roine RP, Lindstrom J,
Erkkola M, et al. Gestational diabetes mellitus can be prevented
by lifestyle intervention: the Finnish gestational diabetes prevention
study (RADIEL): a randomized controlled trial. Diabetes Care.
2016;39(1):24–30. Effects of lifestyle intervention in overweight
women or women with a history of GDM on glucose metabolism in pregnancy.
Harreiter J, Kautzky-Willer A. Sex and gender differences in prevention of Type 2 diabetes. Front Endocrinol. 2018;9:220. https://
doi.org/10.3389/fendo.2018.00220.
Simmons D, van Poppel MN. UPBEAT, RADIEL, and DALI:
what’s the difference? Lancet Diabetes Endocrinol. 2015;3(10):
761.
Shepherd E, Gomersall JC, Tieu J, Han S, Crowther CA, Middleton
P. Combined diet and exercise interventions for preventing

162

51.

52.

Page 10 of 10
gestational diabetes mellitus. Cochrane Database Syst Rev.
2017;11:CD010443.
Song C, Li J, Leng J, Ma RC, Yang X. Lifestyle intervention can
reduce the risk of gestational diabetes: a meta-analysis of randomized controlled trials. Obes Rev. 2016;17(10):960–9.
Powe CE, Allard C, Battista MC, Doyon M, Bouchard L, Ecker JL,
et al. Heterogeneous contribution of insulin sensitivity and secretion
defects to gestational diabetes mellitus. Diabetes Care. 2016;39:
1052–5.

Curr Diab Rep
53.

54.

(2019) 19:162

Santo EC, Forbes PW, Oken E, Belfort MB. Determinants of physical activity frequency and provider advice during pregnancy. BMC
Pregnancy Childbirth. 2017;17(1):286.
Barker ED, Kirkham N, Ng J, Jensen SK. Prenatal maternal depression symptoms and nutrition, and child cognitive function. Br J
Psychiatry. 2013;203(6):417–21.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations
Jürgen Harreiter 1 & Gernot Desoye 2 & Mireille N. M. van Poppel 3 & Alexandra Kautzky-Willer 1 & Fidelma Dunne 4 &
Rosa Corcoy 5,6,7 & Roland Devlieger 8 & David Simmons 9,10 & Juan M. Adelantado & Peter Damm &
Elizabeth Reinhardt Mathiesen & Dorte Moeller Jensen & Lise Lotte T. Anderson & Annunziata Lapolla & Maria G. Dalfrà &
Alessandra Bertolotto & Ewa Wender-Ozegowska & Agnieszka Zawiejska & David J. Hill & Frank J. Snoek & on behalf of the
DALI Consortium
Jürgen Harreiter
juergen.harreiter@meduniwien.ac.at

Fidelma Dunne
fidelma.dunne@nuigalway.ie

Gernot Desoye
gernot.desoye@medunigraz.at

Rosa Corcoy
rcorcoy@santpau.cat

Mireille N. M. van Poppel
mireille.van-poppel@uni-graz.at

Roland Devlieger
roland.devlieger@uz.kuleuven.ac.be

Alexandra Kautzky-Willer
alexandra.kautzky-willer@meduniwien.ac.at

1

Gender Medicine Unit, Division of Endocrinology and Metabolism,
Department of Medicine III, Medical University of Vienna,
Vienna, Austria

2

Department of Obstetrics and Gynecology, Medical University of
Graz, Graz, Austria

3

Institute of Sport Science, University of Graz, Graz, Austria

4

National University of Ireland, Galway, Ireland

5

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain

6

CIBER Bioengineering, Biomaterials and Nanotechnology, Instituto
de Salud Carlos III, Madrid, Spain

7

Departament de Medicina, Universitat Autònoma de Barcelona,
Bellaterra, Spain

8

KU Leuven Department of Development and Regeneration:
Pregnancy, Fetus and Neonate, Gynaecology and Obstetrics,
University Hospitals Leuven, Leuven, Belgium

9

Institute of Metabolic Science, Addenbrookes Hospital,
Cambridge, England

10

School of Medicine, Macarthur Clinical School, Western Sydney
University, Locked Bag 1797, Campbelltown, NSW 2751,
Australia

